The U.S. government is collecting anecdotal social media data on recurring COVID cases in patients who take Pfizer’s Paxlovid five-day treatment course. The move comes as part of the Biden administration strategy to coexist with COVID by offering a cure for those who get it. The studies, which are expected to get underway after an initial data collection, will look at who is at risk for relapse and whether a change in the prescription course could impact that. “It is a priority,” Clifford Lane, deputy director for clinical research at the National Institute of Allergy and Infectious Diseases, told Bloomberg, calling it “a pretty urgent thing for us to get a handle on.” The group is working together with the Centers for Disease Control and Prevention to carry out the studies after a number of people posted about their experiences with COVID symptoms returning after taking the drug.
Read it at Bloomberg
